Phaseline

Companies › Solstice Oncology

Solstice Oncology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Sep 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Porustobart
Toll-like receptor 8 (TLR8) agonist
TLR8Phase 2Colon CancerSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07808151PorustobartPhase 2Colon CancerOncologySep 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

TLR8 (1)

Companies with the same targets

Merck KGaA Eikon Therapeutics United Immunity Beeline Medicines HighField Biopharmaceuticals Ascendis Pharma Oncology Division Bolt Biotherapeutics Inimmune

Companies built like this

CatalYm Alethia Biotherapeutics CrystalGenomics Partner Therapeutics STCube

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.